Caliper Life Sciences Receives $1.1 Million Task Order from the EPA’s ToxCast(TM) Screening Program

              - Caliper Screens Compounds to Detect Toxicity -



    HOPKINTON, Mass., Aug. 19 /EMWNews/ -- Caliper Life

Sciences, Inc. (Nasdaq: CALP) today announced that it has received a $1.1

million task order under the United States Environmental Protection

Agency's (EPA) ToxCast(TM) screening program. This task order was issued

pursuant to a contract that Caliper was awarded by the EPA in April 2007

under the ToxCast program. The contract provides for up to $69 million of

screening services throughout five years, although the specific dollar

value is subject to the actual volume of testing requested by the EPA as

well as continued government funding for the ToxCast program. To date,

Caliper has received task orders under this EPA contract totaling

approximately $3.6 million, including the new $1.1million task order. This

new task order was anticipated and the work associated with this order is

expected to be substantially completed during the third quarter of 2008.



    Caliper works with the EPA under the ToxCast initiative to develop new

approaches to identify chemical compounds that are potentially toxic to the

environment. Caliper uses in vitro biochemical assays, which have been

validated in the pharmaceutical drug discovery industry, to help predict

how chemicals like pesticides will interact with the environment, humans

and animals. During the initial phase, Caliper tested 320 well-known

chemicals through more than 230 in vitro assays. The new task order will

support further screening of this initial set of 320 compounds.



    Once the first phase of the ToxCast program is complete, the EPA is

expected to begin screening a broader class of compounds to expand the

database of bioactivity signatures developed in the first phase. Based on

these efforts, the ToxCast screening program will provide the EPA with an

efficient tool for rapidly and efficiently screening compounds and

prioritizing further toxicity testing. The ultimate goal is to identify a

set of predictive in vitro assays that can supplement or replace in vivo

tests currently used for regulatory approval of new environmental

chemicals.



    "Caliper's test results from the initial phase of the ToxCast screening

program provided high quality data and demonstrated a substantial number of

positive results, or 'hits,' that may have potential relevance to

environmental toxicity or adverse effects. With this new funding, we will

expand our testing to determine the potency, or concentration response, of

these bioactivities using all 230 of the initial assays," said David

Manyak, Ph.D., executive vice president of discovery services at Caliper

Life Sciences. "This follow-up screening is an important step in the

progress of the ToxCast program. We look forward to continuing our research

efforts and supporting the EPA's efforts to better understand the impact,

and minimize the threat, of environmental contaminants."



    Earlier in 2008, the EPA and National Institutes of Health (NIH)

announced a collaboration intended to broaden the scope of the ToxCast

screening program beyond the EPA, further emphasizing the growing national

significance of this initiative. Caliper was selected and will present the

methodology and validated results of a series of toxicology-related

cell-based assays at the National Toxicology Program's Request for

Information Meeting, to be held on September 11-12 in North Carolina. The

event is sponsored by the National Institute of Environmental Health

Sciences (NIEHS), one of the two lead agencies within National Institutes

of Health (NIH) spearheading the collaboration with EPA.

    About Caliper Life Sciences



    Caliper Life Sciences is a premier provider of cutting-edge

technologies enabling researchers in the life sciences industry to create

life-saving and enhancing medicines and diagnostic tests more quickly and

efficiently. Caliper is aggressively innovating new technology to bridge

the gap between in vitro assays and in vivo results and then translating

those results into cures for human disease. Caliper's portfolio of

offerings includes state-of-the-art microfluidics, lab automation & liquid

handling, optical imaging technologies, and discovery & development

outsourcing solutions. For more information please visit

http://www.caliperLS.com.



    The statements in this press release regarding future events, including

statements regarding the total amount of task orders that may be awarded to

Caliper by the EPA under Caliper's contract with the EPA for its ToxCast

screening program, Caliper's expectation that it will be able to

substantially complete the work associated with the new task order during

the third quarter, and the expectation that the EPA will begin screening a

broader class of compounds after the completion of the initial set of

compounds, are "forward-looking statements" within the meaning of Section

21E of the Securities Exchange Act of 1934, as amended. These statements

are subject to risks and uncertainties that could cause actual results to

differ materially from those contemplated by the forward-looking statements

as a result of a number of factors, including the possibility that the EPA

may decide to discontinue the ToxCast screening program or that funding

levels for this program may be less than expected. Further information on

risks faced by Caliper are detailed under the caption "Risks Related To Our

Business" in Caliper's Annual Report on Form 10-K for the year ended

December 31, 2007. Our filings are available on a web site maintained by

the Securities and Exchange Commission at http://www.sec.gov. Caliper does

not undertake any obligation to update forward-looking or other statements

in this release.



    Caliper is a registered trademark of Caliper Life Sciences, Inc. and

ToxCast is a trademark of the Environmental Protection Agency.